Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sheel Patel

Pain Medicine Portage, IN Medical Doctor

NPI 1558657346 CMS profile 160964

3630 Willowcreek Rd Ste 9, Portage, IN 46368

Open in the dashboard

General payments

$31,481

320 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sheel Patel of Portage, IN is reported in the CMS Open Payments database as having received $31,481 across 320 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,660 68
2024 General $15,089 65
2023 General $3,064 39
2022 General $1,780 37
2021 General $1,159 38
2020 General $3,778 34
2019 General $2,952 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheel Patel
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Sheel Patel were reported at $3,660. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Sheel Patel Pain Medicine median Middle half National median
2019 $2,952 $498 $126–$1,682 $163
2020 $3,778 $284 $80–$910 $114
2021 $1,159 $399 $112–$1,219 $132
2022 $1,780 $455 $137–$1,484 $149
2023 $3,064 $484 $128–$1,495 $160
2024 $15,089 $498 $131–$1,540 $164
2025 $3,660 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $8,443 146 payments
  2. Vertos Medical, Inc. $7,858 22 payments
  3. Stryker Corporation $6,324 14 payments
  4. Medtronic USA, Inc. $1,731 18 payments
  5. Nalu Medical, Inc. $1,487 8 payments
  6. Saluda Medical Americas, Inc. $942 14 payments
  7. Zavation LLC $901 6 payments
  8. Boston Scientific Corporation $781 13 payments
  9. SurGenTec $553 1 payment
  10. Globus Medical, Inc. $418 17 payments
  11. Other $2,044 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,075 300 payments
  2. Consulting Fee $11,625 10 payments
  3. Travel and Lodging $4,782 10 payments
Products named General payments · program years 2019–2025
  1. mild Device Kit Orthopedic $7,858 22 payments
  2. MILD DEVICE KIT Instruments $5,750 4 payments
  3. Proclaim Family of SCS IPGs $3,185 39 payments
  4. PROCLAIM Neuromodulation $2,790 57 payments
  5. Nalu Neurostimulation System $1,487 8 payments
  6. INTELLIS $1,345 12 payments
  7. Proclaim IPG $637 16 payments
  8. Evoke $586 11 payments
  9. TiLink, Ion $553 1 payment
  10. PROCLAIM Neuromodulation $541 5 payments
  11. Other $6,246 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,675

Median for Pain Management: 951

Drug cost

$28,090

Median for Pain Management: $26,034

Branded share of claims

27.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 163 $6,730
Gabapentin Generic 218 $5,095
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 250 $4,993
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 84 $2,697
Acetaminophen-Codeine Acetaminophen With Codeine Brand 123 $1,836
Diclofenac Sodium Generic 158 $1,554
Tizanidine Hcl Generic 231 $1,462
Celecoxib Generic 15 $535
Cephalexin Generic 53 $395
Methylprednisolone Generic 75 $394

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$224,656

Of which drugs: $857

Medicare patients

410

Average age 72

Services billed

3,495

273 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 40%
Ischemic heart disease 37%
Depression 32%
Chronic kidney disease 28%
COPD 28%
Heart failure 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 730 $72

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record